Effect of atropine on sputum production

M. T. LOPEZ-VIDRIERO, J. COSTELLO 1, T. J. H. CLARK, I. DAS, E. E. KEAL, and L. REID

Department of Experimental Pathology, Cardiothoracic Institute, Brompton Hospital, London SW3 and Department of Medicine, The Royal Infirmary, Edinburgh

Lopez-Vidriero, M. T., Costello, J., Clark, T. J. H., Das, I., Keal, E. E., and Reid, Lynne (1975). Thorax, 30, 543-547. Effect of atropine on sputum production. The effect of atropine on sputum production has been studied in patients with asthma, chronic bronchitis, and bronchiectasis in some of whom there was bronchorrhea. In three patients a reduction in sputum volume was observed after atropine but it would seem that the decrease was mainly due to the inhibitory effect on salivary secretion which facilitates spitting. The one patient treated with long-term oral atropine showed a marked reduction in sputum volume although chemical constituents and viscosity levels remained unchanged, suggesting that in this case atropine had an inhibitory effect on bronchial gland secretion.

In recent years attention has been focused on the role played by the parasympathetic nervous system in non-antigenic and antigenic-induced bronchoconstriction. Studies carried out in laboratory animals and in asthmatic and chronic bronchitic patients (Hume and Rhys, 1961; Sterling, 1967; Simonsson, Jacobs, and Nadel 1967; Yu, Galant, and Gold, 1972) have shown that stimulation of irritant receptors by citric acid, charcoal dust, cold air, histamine aerosol, cigarette smoke, rapid respiratory manoeuvres or antigen challenge result in bronchoconstriction, and that this reflex bronchoconstriction is largely blocked by atropine.

Atropine has long been used to inhibit saliva and bronchial secretion and, indirectly, laryngospasm before administration of anaesthetic (Eger, Kraft, and Keasling, 1961; Freeman and Bachman, 1959; Pohto and Ahtee, 1966). Organ culture studies carried out with human bronchial explants (Sturgess and Reid, 1972a and b) have shown that atropine reduces the secretory activity of mucous and serous glands, although complete inhibition was not achieved.

Since the beginning of the 19th century (Sigmoid, 1836) atropine has been used, either alone or in combination with other bronchodilators, in the treatment of reversible airways obstruction (Beak e y et al., 1949; Dautreband and Heymans, 1959; Chamberlain, Muir, and Kennedy, 1962; Yu et al., 1972) but the reports that it slows mucous transport rate and ciliary beating (Blair and Woods, 1969) and may alter the physical properties of the mucus layer (Basch, Holinger, and Poncher, 1941) have restricted its clinical use.

It has been widely accepted that atropine increases the viscosity of bronchial secretion and impairs the ciliary clearing, thus causing retention of mucus and airways obstruction, but there is little evidence to support this. The effect of atropine on bronchial secretions of bronchiectatic patients was studied during bronchoscopy (Basch et al., 1941) and less, but more viscous, secretion adherent to the bronchial mucosa was reported. Blanshard (1960) reported no change in sputum viscosity in postoperative patients with chronic bronchitis before or after atropine.

Our study was designed to assess the effect of atropine on sputum volume, viscosity, and chemical constituents in a group of patients with airflow obstruction from various causes.

PATIENTS AND METHODS

Nine male patients who complained of constant cough and sputum were studied; their ages ranged from 18 to 80 years, the mean being 46.2 years (Table I). Five of these had asthma, two had bronchiectasis, and two had chronic bronchitis (Medical Research Council, 1965).

The patients were selected because they produced sputum rather than for the underlying
cause of this. Since patients 1, 7, and 8 produced over 100 ml of sputum daily, they were considered to have bronchorrhoea also (Keal, 1971; Lopez-Vidriero et al., in preparation); bronchorrhoea was associated with intrinsic asthma in two patients and with bronchiectasis in one.

Atropine was administered by inhalation in three patients (via a Wright's nebulizer), by intramuscular injection in five patients, and orally in one patient (Table I). The inhaled and intramuscular atropine was administered between 09:30 and 10:00 hours on the treatment day. Atropine methonitrate was used for inhalation, and atropine sulphate for oral and intramuscular administration. If the patient did not have a dry mouth or a greater than 10% rise in pulse rate after the first dose of atropine, the dose was doubled the next day (patients 2 and 7, Table I) and, in this way, atropine effect was induced in every patient. Patient 5 was studied as an outpatient and did not have his pulse rate recorded. Patient 1 had long-term oral atropine.

SPUTUM STUDIES The daily sputum volume was measured, and sputum samples were collected at three-hour intervals from 06:00 to 21:00 hours on the day of atropine administration and two or three days before treatment. The sputum produced from 06:00 to 15:00 hours was used for viscosity and chemical studies, using a Ferranti-Shirley viscometer, over a shear rate of 0–1800 sec⁻¹.

The remainder of the sputum was frozen at −20°C and stored at the same temperature until chemical analysis was carried out. Preliminary treatment of sputum included boiling at 100°C for 10 minutes to destroy salivary and bacterial enzymes (neuraminidase and aldolase) and dialysis (Visking tube 18/32) against distilled water at 4°C for 72 hours. The following chemical estimations were carried out: macromolecular material (Warren, 1959), N-acetyl-neuraminic acid (Warren, 1959), and methyl-pentose-fucose (Gibbons, 1955).

RESULTS VOLUME The mean values for the 24-hour and three-hour sputum volumes after atropine treatment were compared with mean values obtained during control days. Two patients (3 and 9, Table II) failed to produce any sputum in the three hours after intramuscular atropine sulphate (0·6 mg) but, in both, the amount expectorated

### Table I

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>Route</th>
<th>Dose (mg bd)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 1</td>
</tr>
<tr>
<td>1</td>
<td>44</td>
<td>M</td>
<td>Intrinsic asthma + bronchorrhoea</td>
<td>Oral</td>
<td>0-3</td>
</tr>
<tr>
<td>2</td>
<td>48</td>
<td>M</td>
<td>Extrinsic asthma</td>
<td>Inhalation</td>
<td>1-2</td>
</tr>
<tr>
<td>3</td>
<td>80</td>
<td>M</td>
<td>Chronic bronchitis</td>
<td>Intramuscular</td>
<td>0-6</td>
</tr>
<tr>
<td>4</td>
<td>53</td>
<td>M</td>
<td>Extrinsic asthma</td>
<td>Inhalation</td>
<td>0-6</td>
</tr>
<tr>
<td>5</td>
<td>18</td>
<td>M</td>
<td>Bronchiectasis</td>
<td>Intramuscular</td>
<td>0-6</td>
</tr>
<tr>
<td>6</td>
<td>46</td>
<td>M</td>
<td>Chronic bronchitis</td>
<td>Intramuscular</td>
<td>0-6</td>
</tr>
<tr>
<td>7</td>
<td>49</td>
<td>M</td>
<td>Intrinsic asthma + bronchorrhoea</td>
<td>Intramuscular</td>
<td>0-6</td>
</tr>
<tr>
<td>8</td>
<td>36</td>
<td>M</td>
<td>Bronchiectasis + bronchorrhoea</td>
<td>Intramuscular</td>
<td>0-6</td>
</tr>
<tr>
<td>9</td>
<td>42</td>
<td>M</td>
<td>Intrinsic asthma</td>
<td>Intramuscular</td>
<td>0-6</td>
</tr>
</tbody>
</table>

### Table II

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sputum Volume (ml)</th>
<th>Apparent Viscosity at 1350 sec⁻¹ (poise)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control Day</td>
<td>Atropine Day</td>
</tr>
<tr>
<td></td>
<td>06-09 hr</td>
<td>09-12 hr</td>
</tr>
<tr>
<td>1</td>
<td>54</td>
<td>12</td>
</tr>
<tr>
<td>2</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>2-5</td>
</tr>
<tr>
<td>4</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>6</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td>7</td>
<td>50</td>
<td>18</td>
</tr>
<tr>
<td>8</td>
<td>1</td>
<td>0-5</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
before atropine was very small—1 and 2 ml respectively, and the 24-hour volume remained within control values. These two patients complained of marked dryness of mouth and difficulty in coughing up phlegm from the back of the throat. Another patient (8), in whom atropine seemed to have some effect, had bronchiectasis and was thought to have bronchorrhoea, although our studies showed that the 'sputum' was mainly saliva. He showed a significant reduction in the three-hour sputum volume, but the 24-hour volume remained within the control range (Table II).

VISCOSITY AND CHEMICAL RESULTS Neither viscosity nor chemical constituents were consistently affected by atropine (Tables II and III).

For each individual patient the levels for apparent viscosity at a shear rate of 1350 sec	extsuperscript{-1} and for chemical constituents—dry weight, neuraminic acid, and fucose concentration—fell within the range for their disease group. In two patients (4 and 7, Table II) the apparent viscosity increased on the second day of atropine administration, and in patient 7 it coincided with an increase in the dose of atropine.

There was no significant difference, even at the 10% level, between the results obtained for sputum volume, viscosity, and chemical constituents for the corresponding periods on control and treatment days, nor was there any significant difference before and after treatment on the treatment day itself.

RESPONSE OF BRONCHORRHOEA TO LONG-TERM ATROPINE In patient 1 (Table II) the effect was noted after long-term atropine. He had been receiving corticosteroid treatment, 10 mg/day, for the previous five years. Two months before atropine was started, prednisone had been increased to 35 mg daily and he was also given beclomethasone dipro-nionate, 200 μg four times a day, but no effect on sputum volume was observed. When oral atropine was started, prednisone was increased to 60 mg daily but then gradually reduced to only 10 mg. Atropine was started at a dose of 0.3 mg twice daily and was gradually increased during the five weeks study period to 0.6 mg four times a day (Figure). The 24-hour sputum volume showed a marked reduction during the last three weeks of the study when atropine levels were at their highest and prednisone levels at their lowest. Chemical constituents and viscosity, even of the small amount of residual sputum, did not change and fell within the values found for prostaglandin F	extsubscript{2α}-stimulated bronchial secretion (Lopez-Vidriero et al., in preparation).

FIGURE Reduction in sputum volume in patient 1 by atropine after failure to respond to prednisone.

DISCUSSION

Our study confirms Blanshard's (1960) findings since viscosity and also dry weight yield, neuraminic acid, and fucose varied little after atropine. Since studies of the human bronchial glands in organ culture (Sturgess and Reid, 1972a and b)
have shown that atropine has a depressant effect on the secretion from both mucous and serous cells of the submucosal glands, it is somewhat surprising that our studies revealed practically no effect on the volume and constituents of secretion. On the other hand, organ culture studies also showed that gland hypertrophy affects sensitivity to drugs; that is, the larger the gland—expressed as a gland/wall ratio (Reid, 1960)—the less the inhibitory effect of a given dose of atropine.

The two patients in whom secretion dried up produced small amounts of sputum and, presumably, had little if any gland hypertrophy: both complained of marked dryness of the mouth. It seems that in these patients the effect of atropine was mainly on the salivary secretion, thus affecting the expulsion of bronchial secretion by reducing the ‘lubricating action’ of saliva, as reported by Hillis (1952). The reduction in sputum volume observed in one patient with ‘bronchorhoea’ associated with bronchiectasis could also be explained by the inhibitory effect of atropine on salivary secretion since our studies showed that most of the ‘sputum’ produced had chemical and rheological characteristics of saliva.

The features of the response of the patient with bronchorhoea to long-term atropine are different from the pattern of response to prednisone described by Keal (1971). In some of Keal’s patients with bronchorhoea associated with asthma, a fall in sputum volume was accelerated by prednisone, and the concentration of dry weight and neuraminic acid suggested an increased concentration of the secretion, perhaps by altering the tissue fluid component. In the present study the decrease in sputum volume after atropine, without any change in chemical constituents, suggests an inhibitory effect on bronchial gland secretion. Since the patient on oral atropine had intrinsic asthma, minimal gland hypertrophy would be expected and this should be susceptible to inhibition by atropine. It seems that excessive bronchial secretion may be of two types—one susceptible to atropine and the other to prednisone.

REFERENCES


Medical Research Council (1965). Definition and classification of chronic bronchitis. Committee on the Aetiology of Chronic Bronchitis, Lancet, 1, 775.


Sigmond, G. G. (1836). Lectures on materia medica and therapeutics now in course of delivery at The Windmill School of Medicine, Lecture 17. Lancet, 2, 392.


Requests for reprints to: Professor Lynne Reid, Department of Experimental Pathology, Cardio-thoracic Institute, Brompton Hospital, London SW3.
Effect of atropine on sputum production.

M T Lopez-Vidriero, J Costello, T J Clark, I Das, E E Keal and L Reid

Thorax 1975 30: 543-547
doi: 10.1136/thx.30.5.543

Updated information and services can be found at:
http://thorax.bmj.com/content/30/5/543

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/